STEP 1 Trial Wilding et al., New England Journal of Medicine (2021) Wilding and colleagues conducted the Semaglutide Treatment Effect in People with Obesity (STEP 1) trial: a 68-week, double-blind, randomized, placebo-controlled phase 3 trial conducted at 129 sites across 16 countries
P-32 Survey results from Italy, the US, UK, and France: Anxiety in patients using injectable on-demand treatments for hereditary angioedema attacks Mauro Cancian 1 , Alexis Bocquet 2 , Paula J
For lip lightening & genetic cause of pigmentation, 4 sessions, spaced 2-4 weeks apart
The NF-kB connection GLP-1 receptor activation, whether by natural GLP-1 or pharmaceutical agonists, inhibits the nuclear factor kappa-B (NF-kB) inflammatory pathway
This can further increase inflammation and oxidative stress